Ziprasidone
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
First Episode Psychosis
Conditions
First Episode Psychosis
Trial Timeline
— → May 1, 2010
NCT ID
NCT01157559About Ziprasidone
Ziprasidone is a approved stage product being developed by Pfizer for First Episode Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01157559. Target conditions include First Episode Psychosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01157559 | Approved | Completed |
| NCT02935998 | Approved | UNKNOWN |
| NCT01293825 | Approved | Completed |
| NCT01198353 | Approved | Completed |
| NCT00579670 | Pre-clinical | Completed |
| NCT00454883 | Pre-clinical | Completed |
| NCT00406315 | Approved | Completed |
| NCT00421954 | Phase 3 | Completed |
| NCT01053429 | Pre-clinical | Completed |
| NCT00458211 | Approved | Completed |
| NCT00237666 | Approved | Completed |
| NCT00351000 | Approved | Completed |
| NCT00137020 | Approved | Completed |
| NCT00645229 | Phase 3 | Terminated |
| NCT00649064 | Approved | Completed |
| NCT00650429 | Approved | Completed |
| NCT00395031 | Phase 2/3 | Completed |
| NCT00645320 | Approved | Completed |
| NCT00644800 | Approved | Completed |
| NCT00143351 | Phase 3 | Completed |
Competing Products
12 competing products in First Episode Psychosis